Synopsis
0
VMF
0
Australia
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
Annual Reports
NA
1. 5-(4-(2-(5-ethyl-2-pyridyl)ethoxy)benzyl)-2,4-thiazolidinedione
2. Actos
3. Ad 4833
4. Ad-4833
5. Ad4833
6. Pioglitazone
7. U 72107a
8. U-72107a
9. U72,107a
10. U72107a
1. 112529-15-4
2. Pioglitazone Hcl
3. Actos
4. Piomed
5. 5-(4-(2-(5-ethylpyridin-2-yl)ethoxy)benzyl)thiazolidine-2,4-dione Hydrochloride
6. U-72107a
7. Pioglitazone (hydrochloride)
8. Ad 4833
9. U 72107a
10. Jqt35npk6c
11. U-72107e
12. Pioglitazone (as Hydrochloride)
13. Str-001
14. [5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-2,4-] Thiazolidinedione Hydrochloride
15. Nsc-758876
16. Ncgc00095131-01
17. Pioditazone Hydrochloride
18. 5-[4-[2-(5-ethyl-2-pyridyl)ethoxy]benzyl]thiazolidine-2,4-dione Hydrochloride
19. Actos (tn)
20. Dsstox_cid_24203
21. Dsstox_rid_80116
22. Dsstox_gsid_44203
23. 5-[[4-[2-(5-ethylpyridin-2-yl)ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione;hydrochloride
24. 2,4-thiazolidinedione, 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-, Monohydrochloride
25. Smr000469167
26. Cas-112529-15-4
27. Pioglitazone Hydrochloride [usan]
28. Unii-jqt35npk6c
29. 5-(4-[2-(5-ethyl-pyridin-2-yl)-ethoxy]-benzyl)-thiazolidine-2,4-dione Hydrochloride
30. 5-[4-[2-(5-ethyl-pyridin-2-yl)-ethoxy]-benzyl]-thiazolidine-2,4-dione Hydrochloride
31. 5-{4-[2-(5-ethyl-pyridin-2-yl)-ethoxy]-benzyl}-thiazolidine-2,4-dione Hydrochloride
32. 2,4-thiazolidinedione, 5-((4-(2-(5-ethyl-2-pyridinyl)ethoxy)phenyl)methyl)-, Monohydrochloride
33. Mfcd04975446
34. Poze
35. Pioglitazone Hydrochloride [usan:usp]
36. Pioglitazone Cloridrato
37. Pioglitazonehydrochloride
38. Cloridrato De Pioglitazona
39. Pioglitazone, Hydrochloride
40. Clorhidrato De Pioglitazona
41. Chlorhydrate De Pioglitazone
42. (+-)-5-(p-(2-(5-ethyl-2-pyridyl)ethoxy)benzyl)-2,4-thiazolidinedione Monohydrochloride
43. 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-2,4-thiazolidinedione Monohydrochloride
44. Chembl1715
45. Schembl21843
46. Mls001306462
47. Mls001401386
48. Spectrum1504401
49. Chebi:8229
50. Dtxsid3044203
51. Pioglitazone Hcl [vandf]
52. Pioglitazone Hydrochloride ,(s)
53. Pioglitazone Hydrochloride- Bio-x
54. Hms1922l05
55. Pioglitazone Hydrochloride (actos)
56. Act04238
57. Bcp22942
58. Tox21_111440
59. Tox21_300584
60. Ccg-39097
61. S2046
62. Akos015844016
63. Tox21_111440_1
64. Ac-1037
65. Ccg-100931
66. Ks-1186
67. Nc00181
68. Nsc 758876
69. Pioglitazone Hydrochloride (jp17/usp)
70. Pioglitazone Hydrochloride [mi]
71. Sb17324
72. Pioglitazone Hydrochloride [jan]
73. Ncgc00095131-02
74. Ncgc00163128-08
75. Ncgc00254492-01
76. 2,4-thiazolidinedione, 5-((4-(2-(5-ethyl-2-pyridinyl)ethoxy)phenyl)methyl)-, Monohydrochloride, (+-)-
77. Aa-10090
78. Bp164272
79. Hy-14601
80. Pioglitazone Hydrochloride [mart.]
81. Pioglitazone Hydrochloride [vandf]
82. Bcp0726000151
83. Pioglitazone Hydrochloride [usp-rs]
84. Pioglitazone Hydrochloride [who-dd]
85. Pioglitazone Hydrochloride, >=98% (hplc)
86. Am20061770
87. Ft-0601607
88. P1901
89. Sw197561-4
90. D00945
91. Pioglitazone Hydrochloride [orange Book]
92. Oseni Component Pioglitazone Hydrochloride
93. Pioglitazone Hydrochloride [ep Monograph]
94. 025p468
95. A802593
96. Duetact Component Pioglitazone Hydrochloride
97. Pioglitazone Hydrochloride [usp Monograph]
98. Pioglitazone Hydrochloride Component Of Oseni
99. Q-201584
100. Pioglitazone Hydrochloride 100 Microg/ml In Methanol
101. Pioglitazone Hydrochloride Component Of Duetact
102. Q27281642
103. Actoplus Met Component Pioglitazone Hydrochloride
104. Pioglitazone Hydrochloride Component Of Actoplus Met
105. 5-(4-(2-(5-ethylpyridin-2-yl)ethoxy)benzyl)thiazolidine-2,4-dione Hcl
106. Pioglitazone Hydrochloride, European Pharmacopoeia (ep) Reference Standard
107. 5-((4-(2-(5-ethyl-2-pyridinyl)ethoxy)phenyl)methyl)-2,4-thiazolidinedione, Hcl
108. 5-(4-[2-(5-ethyl-pyridin-2-yl)-ethoxy]-benzyl)-thiazolidine-2,4-dione Hcl
109. 5-[[4-[2-(5-ethyl-2-pyridinyl)-ethoxy]phenyl]methyl]-2,4-thiazolidinedione Hydrochloride
110. 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-2,4-thiazolidinedione, Hydrochloride
111. 5-[4-[2-(5-ethyl-2-pyridyl)ethoxy]benzyl]-2,4-thiazolidinedione Hydrochloride
112. 5-{4-[2-(5-ethylpyridin-2-yl)ethoxy]benzyl}-1,3-thiazolidine-2,4-dione Hydrochloride
113. Pioglitazone For System Suitability, European Pharmacopoeia (ep) Reference Standard
114. Pioglitazone Hydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material
115. Pioglitazone Hydrochloride, United States Pharmacopeia (usp) Reference Standard
116. (+/-)-5-(p-(2-(5-ethyl-2-pyridyl)ethoxy)benzyl)-2,4-thiazolidinedione Monohydrochloride
117. 127676-30-6
118. 2,4-thiazolidinedione, 5-((4-(2-(5-ethyl-2-pyridinyl)ethoxy)phenyl)methyl)-, Hydrochloride (1:1)
119. 2,4-thiazolidinedione, 5-((4-(2-(5-ethyl-2-pyridinyl)ethoxy)phenyl)methyl)-, Monohydrochloride, (+/-)-
Molecular Weight | 392.9 g/mol |
---|---|
Molecular Formula | C19H21ClN2O3S |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 5 |
Rotatable Bond Count | 7 |
Exact Mass | 392.0961414 g/mol |
Monoisotopic Mass | 392.0961414 g/mol |
Topological Polar Surface Area | 93.6 Ų |
Heavy Atom Count | 26 |
Formal Charge | 0 |
Complexity | 466 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 1 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 2 | |
---|---|
Drug Name | Pioglitazone hydrochloride |
Drug Label | ACTOS (pioglitazone hydrochloride) is an oral antidiabetic agent that acts primarily by decreasing insulin resistance. ACTOS is used in the management of type2 diabetes mellitus (also known as non-insulin-dependent diabetes mellitus [NIDDM] or adul... |
Active Ingredient | Pioglitazone hydrochloride |
Dosage Form | Tablet |
Route | Oral |
Strength | eq 15mg base; eq 30mg base; eq 45mg base |
Market Status | Prescription |
Company | Synthon Pharms; Mylan Pharms; Accord Hlthcare; Aurobindo Pharma; Teva Pharms Usa; Torrent Pharms; Lupin; Sandoz; Watson Labs; Macleods Pharms; Zydus Pharms Usa; Dr Reddys Labs |
2 of 2 | |
---|---|
Drug Name | Pioglitazone hydrochloride |
Drug Label | ACTOS (pioglitazone hydrochloride) is an oral antidiabetic agent that acts primarily by decreasing insulin resistance. ACTOS is used in the management of type2 diabetes mellitus (also known as non-insulin-dependent diabetes mellitus [NIDDM] or adul... |
Active Ingredient | Pioglitazone hydrochloride |
Dosage Form | Tablet |
Route | Oral |
Strength | eq 15mg base; eq 30mg base; eq 45mg base |
Market Status | Prescription |
Company | Synthon Pharms; Mylan Pharms; Accord Hlthcare; Aurobindo Pharma; Teva Pharms Usa; Torrent Pharms; Lupin; Sandoz; Watson Labs; Macleods Pharms; Zydus Pharms Usa; Dr Reddys Labs |
Pioglitazone is indicated as second or third line treatment of type-2 diabetes mellitus as described below:
- as
* monotherapy: :
- in adult patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intolerance.
- as
* dual oral therapy: in combination with:
- metformin, in adult patients (particularly overweight patients) with insufficient glycaemic control despite maximal tolerated dose of monotherapy with metformin;
- a sulphonylurea, only in adult patients who show intolerance to metformin or for whom metformin is contraindicated, with insufficient glycaemic control despite maximal tolerated dose of monotherapy with a sulphonylurea;
- as
* triple oral therapy: in combination with:
- metformin and a sulphonylurea, in adult patients (particularly overweight patients) with insufficient glycaemic control despite dual oral therapy.
Pioglitazone is also indicated for combination with insulin in type-2 diabetes mellitus adult patients with insufficient glycaemic control on insulin for whom metformin is inappropriate because of contraindications or intolerance.
After initiation of therapy with pioglitazone, patients should be reviewed after three to six months to assess adequacy of response to treatment (e. g. reduction in HbA1c). In patients who fail to show an adequate response, pioglitazone should be discontinued. In light of potential risks with prolonged therapy, prescribers should confirm at subsequent routine reviews that the benefit of pioglitazone is maintained.
Pioglitazone is indicated in the treatment of type-2 diabetes mellitus as
* monotherapy: :
- in adult patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intolerance.
Pioglitazone is also indicated for combination with insulin in type 2 diabetes mellitus adult patients with insufficient glycaemic control on insulin for whom metformin is inappropriate because of contraindications or intolerance.
After initiation of therapy with pioglitazone, patients should be reviewed after 3 to 6 months to assess adequacy of response to treatment (e. g. reduction in HbA1c). In patients who fail to show an adequate response, pioglitazone should be discontinued. In light of potential risks with prolonged therapy, prescribers should confirm at subsequent routine reviews that the benefit of pioglitazone is maintained.
Pioglitazone is indicated in the treatment of type-2 diabetes mellitus:
* as monotherapy:
- in adult patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intolerance.
After initiation of therapy with pioglitazone, patients should be reviewed after 3 to 6 months to assess adequacy of response to treatment (e. g. reduction in HbA1c). In patients who fail to show an adequate response, pioglitazone should be discontinued. In light of potential risks with prolonged therapy, prescribers should confirm at subsequent routine reviews that the benefit of pioglitazone is maintained.
Pioglitazone is indicated as second or third line treatment of type 2 diabetes mellitus as described below:
* as monotherapy:
- in adult patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intolerance.
* as dual oral therapy in combination with:
- metformin, in adult patients (particularly overweight patients) with insufficient glycaemic control despite maximal tolerated dose of monotherapy with metformin.
- a sulphonylurea, only in adult patients who show intolerance to metformin or for whom metformin is contraindicated, with insufficient glycaemic control despite maximal tolerated dose of monotherapy with a sulphonylurea.
* as triple oral therapy in combination with:
- metformin and a sulphonylurea, in adult patients (particularly overweight patients) with insufficient glycaemic control despite dual oral therapy.
Pioglitazone is also indicated for combination with insulin in type 2 diabetes mellitus adult patients with insufficient glycaemic control on insulin for whom metformin is inappropriate because of contraindications or intolerance (see section 4. 4).
After initiation of therapy with pioglitazone, patients should be reviewed after 3 to 6 months to assess adequacy of response to treatment (e. g. reduction in HbA1c). In patients who fail to show an adequate response, pioglitazone should be discontinued. In light of potential risks with prolonged therapy, prescribers should confirm at subsequent routine reviews that the benefit of pioglitazone is maintained (see section 4. 4).
Pioglitazone is indicated in the treatment of type 2 diabetes mellitus:
- as monotherapy
- in adult patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intolerance
- as dual oral therapy in combination with
- metformin, in adult patients (particularly overweight patients) with insufficient glycaemic control despite maximal tolerated dose of monotherapy with metformin
- a sulphonylurea, only in adult patients who show intolerance to metformin or for whom metformin is contraindicated, with insufficient glycaemic control despite maximal tolerated dose of monotherapy with a sulphonylurea
- as triple oral therapy in combination with
- metformin and a sulphonylurea, in adult patients (particularly overweight patients) with insufficient glycaemic control despite dual oral therapy.
Pioglitazone is also indicated for combination with insulin in type 2 diabetes mellitus adult patients with insufficient glycaemic control on insulin for whom metformin is inappropriate because of contraindications or intolerance.
After initiation of therapy with pioglitazone, patients should be reviewed after 3 to 6 months to assess adequacy of response to treatment (e. g. reduction in HbA1c). In patients who fail to show an adequate response, pioglitazone should be discontinued. In light of potential risks with prolonged therapy, prescribers should confirm at subsequent routine reviews that the benefit of pioglitazone is maintained.
Pioglitazone is indicated as second or third line treatment of type-2 diabetes mellitus as described below:
- as monotherapy:
- in adult patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intolerance;
- as dual oral therapy in combination with:
- metformin, in adult patients (particularly overweight patients) with insufficient glycaemic control despite maximal tolerated dose of monotherapy with metformin;
- a sulphonylurea, only in adult patients who show intolerance to metformin or for whom metformin is contraindicated, with insufficient glycaemic control despite maximal tolerated dose of monotherapy with a sulphonylurea;
- as triple oral therapy in combination with:
- metformin and a sulphonylurea, in adult patients (particularly overweight patients) with insufficient glycaemic control despite dual oral therapy.
Pioglitazone is also indicated for combination with insulin in type-2 diabetes mellitus adult patients with insufficient glycaemic control on insulin for whom metformin is inappropriate because of contraindications or intolerance.
After initiation of therapy with pioglitazone, patients should be reviewed after 3 to 6 months to assess adequacy of response to treatment (e. g. reduction in HbA1c). In patients who fail to show an adequate response, pioglitazone should be discontinued. In light of potential risks with prolonged therapy, prescribers should confirm at subsequent routine reviews that the benefit of pioglitazone is maintained.
Pioglitazone is indicated in the treatment of type-2 diabetes mellitus:
- as
* monotherapy: :
- in patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intolerance;
- as
* dual oral therapy: in combination with:
- metformin, in patients (particularly overweight patients) with insufficient glycaemic control despite maximal tolerated dose of monotherapy with metformin;
- a sulphonylurea, only in patients who show intolerance to metformin or for whom metformin is contraindicated, with insufficient glycaemic control despite maximal tolerated dose of monotherapy with a sulphonylurea;
- as
* triple oral therapy: in combination with:
- metformin and a sulphonylurea, in patients (particularly overweight patients) with insufficient glycaemic control despite dual oral therapy.
Pioglitazone is also indicated for combination with insulin in type-2 diabetes mellitus patients with insufficient glycaemic control on insulin for whom metformin is inappropriate because of contraindications or intolerance.
Pioglitazone is indicated as second or third line treatment of type 2 diabetes mellitus as described below:
* as monotherapy:
- in adult patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intolerance;
as
* dual oral therapy: in combination with
- metformin, in adult patients (particularly overweight patients) with insufficient glycaemic control despite maximal tolerated dose of monotherapy with metformin;
- a sulphonylurea, only in adult patients who show intolerance to metformin or for whom metformin is contraindicated, with insufficient glycaemic control despite maximal tolerated dose of monotherapy with a sulphonylurea;
as
* triple oral therapy: in combination with
- metformin and a sulphonylurea, in adult patients (particularly overweight patients) with insufficient glycaemic control despite dual oral therapy.
Pioglitazone is also indicated for combination with insulin in type 2 diabetes mellitus in adult patients with insufficient glycaemic control on insulin for whom metformin is inappropriate because of contraindications or intolerance.
After initiation of therapy with pioglitazone, patients should be reviewed after 3 to 6 months to assess adequacy of response to treatment (e. g. reduction in HbA1c). In patients who fail to show an adequate response, pioglitazone should be discontinued. In light of potential risks with prolonged therapy, prescribers should confirm at subsequent routine reviews that the benefit of pioglitazone is maintained.
Pioglitazone is indicated as second or third line treatment of type 2 diabetes mellitus as described below:
as monotherapy
- in adult patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intolerance;
as dual oral therapy in combination with
- a sulphonylurea, only in adult patients who show intolerance to metformin or for whom metformin is contraindicated, with insufficient glycaemic control despite maximal tolerated dose of monotherapy with a sulphonylurea;
Pioglitazone is also indicated for combination with insulin in type 2 diabetes mellitus in adult patients with insufficient glycaemic control on insulin for whom metformin is inappropriate because of contraindications or intolerance.
After initiation of therapy with pioglitazone, patients should be reviewed after 3 to 6 months to assess adequacy of response to treatment (e. g. reduction in HbA1c). In patients who fail to show an adequate response, pioglitazone should be discontinued. In light of potential risks with prolonged therapy, prescribers should confirm at subsequent routine reviews that the benefit of pioglitazone is maintained.
Pioglitazone is indicated as second- or third-line treatment of type-2 diabetes mellitus as described below:
* as monotherapy: :
- in adult patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intolerance;
* as dual oral therapy in combination with: :
- metformin, in adult patients (particularly overweight patients) with insufficient glycaemic control despite maximal tolerated dose of monotherapy with metformin;
- a sulphonylurea, only in adult patients who show intolerance to metformin or for whom metformin is contraindicated, with insufficient glycaemic control despite maximal tolerated dose of monotherapy with a sulphonylurea;
* as triple oral therapy in combination with: :
- metformin and a sulphonylurea, in adult patients (particularly overweight patients) with insufficient glycaemic control despite dual oral therapy.
Pioglitazone is also indicated for combination with insulin in type-2-diabetes-mellitus adult patients with insufficient glycaemic control on insulin for whom metformin is inappropriate because of contraindications or intolerance (see section 4. 4).
After initiation of therapy with pioglitazone, patients should be reviewed after three to six months to assess adequacy of response to treatment (e. g. reduction in HbA1c). In patients who fail to show an adequate response, pioglitazone should be discontinued. In light of potential risks with prolonged therapy, prescribers should confirm at subsequent routine reviews that the benefit of pioglitazone is maintained (see section 4. 4).
Hypoglycemic Agents
Substances which lower blood glucose levels. (See all compounds classified as Hypoglycemic Agents.)
A10BG03
A10BG03
A10BG03
A10BG03
A10BG03
A10BG03
A10BG03
A10BG03
A10BG03
A10BG03
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
GDUFA
DMF Review : Reviewed
Rev. Date : 2014-01-14
Pay. Date : 2013-12-31
DMF Number : 21295
Submission : 2008-01-31
Status : Active
Type : II
Registration Number : 303MF10161
Registrant's Address : 8-2-337, Road No. 3, Banjara Hills, Hyderabad 500 034, TELANGANA, INDIA
Initial Date of Registration : 2021-10-27
Latest Date of Registration : --
Date of Issue : 2022-06-17
Valid Till : 2025-07-07
Written Confirmation Number : WC-0067
Address of the Firm :
NDC Package Code : 55111-052
Start Marketing Date : 2012-06-22
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Registrant Name : Pami Future Co., Ltd.
Registration Date : 2022-05-17
Registration Number : 20220517-196-I-633-16
Manufacturer Name : Dr. Reddy's Laboratories Limited
Manufacturer Address : CTO-VI, APIIC Industrial Estate, Pydhibeemavaram, Ranasthalam Mandal, Srikakulam District, Andhra Pradesh - 532 409, India
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 16684
Submission : 2003-07-08
Status : Active
Type : II
Date of Issue : 2022-06-27
Valid Till : 2025-06-02
Written Confirmation Number : WC-0012
Address of the Firm :
NDC Package Code : 62147-0005
Start Marketing Date : 2010-02-04
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Registrant Name : Shinpo Farm Co., Ltd.
Registration Date : 2014-01-08
Registration Number : 20140108-196-I-396-12
Manufacturer Name : USV Limited
Manufacturer Address : B-1/8, MIDC, Lote Parshuram, Industrial Area, Taluka Khed Ratnagiri 415722, Maharashtra State, India.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 16688
Submission : 2003-07-08
Status : Active
Type : II
Date of Issue : 2019-06-17
Valid Till : 2022-05-26
Written Confirmation Number : WC-0002
Address of the Firm :
NDC Package Code : 15894-0017
Start Marketing Date : 2023-03-15
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Available Reg Filing : CA, ASMF |
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 19250
Submission : 2006-03-10
Status : Active
Type : II
NDC Package Code : 62147-0005
Start Marketing Date : 2010-02-04
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Registrant Name : Shinpo Farm Co., Ltd.
Registration Date : 2014-01-08
Registration Number : 20140108-196-I-396-12
Manufacturer Name : USV Limited
Manufacturer Address : B-1/8, MIDC, Lote Parshuram, Industrial Area, Taluka Khed Ratnagiri 415722, Maharashtra State, India.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 19558
Submission : 2006-06-28
Status : Active
Type : II
Certificate Number : R0-CEP 2013-096 - Rev 00
Issue Date : 2014-11-19
Type : Chemical
Substance Number : 2601
Status : Expired
GDUFA
DMF Review : Reviewed
Rev. Date : 2014-02-21
Pay. Date : 2013-09-27
DMF Number : 27504
Submission : 2013-09-19
Status : Active
Type : II
Certificate Number : R1-CEP 2013-143 - Rev 01
Issue Date : 2020-03-06
Type : Chemical
Substance Number : 2601
Status : Valid
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 26192
Submission : 2012-07-03
Status : Inactive
Type : II
Date of Issue : 2022-08-08
Valid Till : 2025-08-09
Written Confirmation Number : WC-0253
Address of the Firm :
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
GDUFA
DMF Review : Complete
Rev. Date : 2014-01-14
Pay. Date : 2013-12-31
DMF Number : 21295
Submission : 2008-01-31
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 19250
Submission : 2006-03-10
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 16684
Submission : 2003-07-08
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 16688
Submission : 2003-07-08
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 16635
Submission : 2003-06-11
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 16672
Submission : 2003-06-30
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 18379
Submission : 2005-05-21
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 17701
Submission : 2004-09-23
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 16682
Submission : 2003-07-03
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 16793
Submission : 2003-08-28
Status : Active
Type : II
Certificate Number : CEP 2019-342 - Rev 01
Status : Valid
Issue Date : 2024-01-12
Type : Chemical
Substance Number : 2601
Pioglitazone Hydrochloride, Process I
Certificate Number : R1-CEP 2014-351 - Rev 00
Status : Valid
Issue Date : 2021-09-23
Type : Chemical
Substance Number : 2601
Certificate Number : R1-CEP 2012-340 - Rev 00
Status : Valid
Issue Date : 2018-10-31
Type : Chemical
Substance Number : 2601
Pioglitazone Hydrochloride, PI-process
Certificate Number : CEP 2023-004 - Rev 00
Status : Valid
Issue Date : 2024-08-30
Type : Chemical
Substance Number : 2601
Certificate Number : R1-CEP 2012-363 - Rev 00
Status : Withdrawn by Holder
Issue Date : 2019-07-17
Type : Chemical
Substance Number : 2601
Pioglitazone Hydrochloride, Process II
Certificate Number : R0-CEP 2017-013 - Rev 01
Status : Withdrawn by Holder
Issue Date : 2019-04-05
Type : Chemical
Substance Number : 2601
Certificate Number : R1-CEP 2013-005 - Rev 00
Status : Valid
Issue Date : 2019-02-20
Type : Chemical
Substance Number : 2601
Certificate Number : CEP 2012-315 - Rev 01
Status : Valid
Issue Date : 2024-07-11
Type : Chemical
Substance Number : 2601
Certificate Number : CEP 2013-077 - Rev 01
Status : Valid
Issue Date : 2024-03-05
Type : Chemical
Substance Number : 2601
Pioglitazone Hydrochloride, Process II
Certificate Number : R1-CEP 2013-143 - Rev 01
Status : Valid
Issue Date : 2020-03-06
Type : Chemical
Substance Number : 2601
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ANALYTICAL
ABOUT THIS PAGE
A Actos manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Actos, including repackagers and relabelers. The FDA regulates Actos manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Actos API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Actos manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Actos supplier is an individual or a company that provides Actos active pharmaceutical ingredient (API) or Actos finished formulations upon request. The Actos suppliers may include Actos API manufacturers, exporters, distributors and traders.
click here to find a list of Actos suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Actos DMF (Drug Master File) is a document detailing the whole manufacturing process of Actos active pharmaceutical ingredient (API) in detail. Different forms of Actos DMFs exist exist since differing nations have different regulations, such as Actos USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Actos DMF submitted to regulatory agencies in the US is known as a USDMF. Actos USDMF includes data on Actos's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Actos USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Actos suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Actos Drug Master File in Japan (Actos JDMF) empowers Actos API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Actos JDMF during the approval evaluation for pharmaceutical products. At the time of Actos JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Actos suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Actos Drug Master File in Korea (Actos KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Actos. The MFDS reviews the Actos KDMF as part of the drug registration process and uses the information provided in the Actos KDMF to evaluate the safety and efficacy of the drug.
After submitting a Actos KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Actos API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Actos suppliers with KDMF on PharmaCompass.
A Actos CEP of the European Pharmacopoeia monograph is often referred to as a Actos Certificate of Suitability (COS). The purpose of a Actos CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Actos EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Actos to their clients by showing that a Actos CEP has been issued for it. The manufacturer submits a Actos CEP (COS) as part of the market authorization procedure, and it takes on the role of a Actos CEP holder for the record. Additionally, the data presented in the Actos CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Actos DMF.
A Actos CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Actos CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Actos suppliers with CEP (COS) on PharmaCompass.
A Actos written confirmation (Actos WC) is an official document issued by a regulatory agency to a Actos manufacturer, verifying that the manufacturing facility of a Actos active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Actos APIs or Actos finished pharmaceutical products to another nation, regulatory agencies frequently require a Actos WC (written confirmation) as part of the regulatory process.
click here to find a list of Actos suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Actos as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Actos API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Actos as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Actos and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Actos NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Actos suppliers with NDC on PharmaCompass.
Actos Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Actos GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Actos GMP manufacturer or Actos GMP API supplier for your needs.
A Actos CoA (Certificate of Analysis) is a formal document that attests to Actos's compliance with Actos specifications and serves as a tool for batch-level quality control.
Actos CoA mostly includes findings from lab analyses of a specific batch. For each Actos CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Actos may be tested according to a variety of international standards, such as European Pharmacopoeia (Actos EP), Actos JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Actos USP).
LOOKING FOR A SUPPLIER?